Which Is Promising As Therapeutic Targets In Patients With Biliary Tract Cancer? EGFR or HER2?
Posted on: Friday, 16 October 2009, 10:31 CDT
The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others. It is unknown if EGFR and HER2 are overexpressed in advanced biliary tract cancer (BTC) and therefore may serve as therapeutic targets in these cancers.
A research article to be published on September 28, 2009 in the World Journal of Gastroenterology addresses this question. A research team from Germany studied EGFR and HER2 expression in biopsy samples from 124 patients (51% women; median age 64.8 years), with advanced BTC diagnosed between 1997 and 2004. Five micrometers sections of paraffin embedded tissue were examined by standard, FDA approved immunohistochemistry. Tumors with scores of 2+ or 3+ for HER2 expression on immunochemistry were additionally tested for HER2 gene amplification by fluorescence in situ hybridisation (FISH). The results showed 34/124 patients (27.4%) had gallbladder cancer, 47 (37.9%) had intrahepatic BTC and 43 (34.7%) had extrahepatic or perihilar BTC. EGFR expression was examined in a subset of 56 samples. EGFR expression was absent in 22/56 tumors (39.3%). Of the remaining samples expression was scored as 1+ in 12 (21.5%), 2+ in 13 (23.2%) and 3+ in 9 (16%), respectively. HER2 expression was as follows: score 0 73/124 (58.8%), score 1+ 27/124 (21.8%), score 2+ 21/124 (17%) and score 3+ 4/124 (3.2%). HER2 gene amplification was present in 6/124, resulting in an overall amplification rate of 5%.
Their findings demonstrate that EGFR overexpression is frequent in BTC. In contrast, HER2 overexpression and gene amplification is a rare event. They concluded that routine testing and therapeutic targeting of HER2 does not seem to be useful in patients with BTC, while targeting EGFR may be promising.
Reference: Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15(36): 4511-4517
---
On the Net:
Related Articles
- Advanced Cancer Therapeutics Licenses Technology to Develop Human Papillomavirus (HPV) Vaccine
- Advanced Cancer Therapeutics Secures Exclusive License to Second Anti-Cancer Therapeutic From the University of Louisville's Brown Cancer Center
- North Shore Radiation Therapy Opens on Long Island, Offers Cancer Patients Access to New, Advanced Cancer Treatments
- Results of RTA 402 Phase I Cancer Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
- Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Array BioPharma to Present Clinical Data at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- EpiCept Initiates Advanced Cancer Study
- Genmab Announces Encouraging Efficacy Data From HuMax-EGFr Phase I/II Trial in Head and Neck Cancer
- University of Pittsburgh; A cell-mediated approach to sFlt-1 gene therapy targets thyroid cancer
- Follicular Thyroid Carcinoma; A cell-mediated approach to sFlt-1 gene therapy targets thyroid cancer
 |
 |
User Comments (0)
RSS Feeds